Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) today and set a price target of $19.00.

Emily Bodnar’s rating is based on the promising clinical data and strategic advancements made by Acrivon Therapeutics, Inc. The company’s ACR-368 has shown significant efficacy in treating endometrial cancer, particularly in OncoSignature-positive patients, with a confirmed overall response rate of 35% and a disease control rate of 80%. These results are notably higher than previous therapies, indicating a strong potential for ACR-368 to outperform standard treatments.
Additionally, Acrivon’s progress in its Phase 1 trial of ACR-2316, which has shown early signs of clinical activity, further supports the Buy rating. The company’s advancements in its Generative Phosphoproteomics platform, aimed at enhancing drug discovery and development, also contribute to the positive outlook. These factors collectively suggest a favorable trajectory for Acrivon’s therapeutic offerings, justifying the Buy recommendation.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.